A phase II single-arm open-label multi-center study of

Recruiting

18 years - 80 years

All

Phase 2

20 participants needed

1 Location

Brief description of study

The purpose of this study is to determine the effects of sirolimus in patients (males or females aged 18-80) with idiopathic multicentric Castleman Disease (iMCD) who are either unable to tolerate siltuximab or tocilizumab, or have failed, relapsed, or are refractory to this treatment. Subjects will take sirolimus daily for 12 months. During this time, the study team will collect data from tests and procedures done as per standard of care. In addition, they will collect research samples.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: castleman,castlemans,iMCD,MCD
Age: 18 years - 80 years
Gender: All

Updated on 04 Aug 2024. Study ID: 832465

Find a site

Your Information has been sent successfully.

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.

Would you like to be notified about other trials? Sign up for Patient Notification Services.

Send a message

Enter your contact details to connect with study team

Primary Contact

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Are you comfortable with the informed consent process?

Yes

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

A phase II single-arm open-label multi-center study of sirolimus in previously treated idiopathic multicentric Castleman disease

Brief description of study

Eligibility of study

Find a site

Interested in the study